Lehrl 2004.

Methods	Randomised, placebo‐controlled double‐blind, multicenter; 2 parallel groups
Participants	Patients with sleep disturbances associated with nonpsychotic anxiety (DSM‐III‐R) ; HAMA total score 16 or above (intention‐to‐treat; n=57); 3 centers in Germany
Interventions	200 mg once (140 mg kavalactones) daily for 4 weeks
Outcomes	HAM‐A total score. Mean difference, 95% confidence interval 1.4; ‐3.4 to 6.2
Notes	Adverse events (kava group): none Jadad score: 4
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear